Galanin diminishes cortical spreading depolarization across rodents - A candidate for treatment?

Cortical Spreading Depolarization (CSD) Galanin Galanin receptor (GalR) Neuronal excitability Rodent

Journal

Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130

Informations de publication

Date de publication:
07 May 2024
Historique:
received: 19 03 2024
revised: 29 04 2024
accepted: 06 05 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

Galanin (Gal) is a neuropeptide with the potential to ameliorate cortical spreading depolarization (CSD), an electrophysiological phenomenon occurring after brain injury or in migraine aura. Gal is expressed in all cortical neurons both in rat and in mouse cortices. Here we investigated whether the effect of Gal on CSD previously described in the rat is conserved in the mouse cortex. In rats, the topical application of Gal to the cortex for 1 h did not induce any change in CSD amplitudes, propagation velocity, or threshold of elicitation. Rather, topical application of Gal for 3 h was necessary to obtain a significant decrease in these CSD parameters and to develop a remarkable increase in the KCl threshold to elicit a CSD in rat cortex. In contrast, the topical application of Gal on cortical surface for 1 h in mice was sufficient to significantly attenuate CSD amplitudes and increase threshold. A thinner cortex, a faster diffusion or different affinity/expression of receptors for Gal are possible reasons to explain this difference in the time course between rats and mice. Our data are relevant to postulate Gal as a potential target for inhibition of CSD under pathological situations such as stroke or ischemia. SIGNIFICANCE STATEMENT: The neuropeptide Galanin is expressed in all neurons throughout the cerebral cortex, both in rats and mice, and is able to reduce or even inhibit Cortical Spreading Depolarization, thus, Galanin has the potential to control neuronal excitability that may identify Galanin as a target in drug development against CSD.

Identifiants

pubmed: 38723760
pii: S0304-3940(24)00191-5
doi: 10.1016/j.neulet.2024.137814
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

137814

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Fátima Gimeno-Ferrer (F)

Institute of Physiology 1/Neurophysiology, Jena University Hospital, D-07740 Jena, Germany.

Annett Eitner (A)

Department of Trauma, Hand and Reconstructive Surgery, Experimental Trauma Surgery, Jena University Hospital, D-07740 Jena, Germany.

Hans-Georg Schaible (HG)

Institute of Physiology 1/Neurophysiology, Jena University Hospital, D-07740 Jena, Germany.

Frank Richter (F)

Institute of Physiology 1/Neurophysiology, Jena University Hospital, D-07740 Jena, Germany. Electronic address: Frank.Richter@med.uni-jena.de.

Classifications MeSH